ALK+   

Questions discussed in this category


Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?

The ALTA and ALEX trials showed better PFS with brigatinib v. crizotinib and alectinib v. crizotinib. How do you choose your first...

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?

What is the current data regarding acquired resistance mutations for ALK?  Should newer agents such as lorlatinib be reserved for later lines a...

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...


Papers discussed in this category


The New England journal of medicine, 2015-10-22

The New England journal of medicine, 2016-11-10

J Thorac Oncol,

Clin. Cancer Res., 2015 May 27

Lancet (London, England), 2017-01-21

Lancet (London, England), 2016-04-09

The New England journal of medicine, 2018-06-14

The Lancet. Respiratory medicine, 2019-05

Ann. Oncol.,

The New England journal of medicine, 2018-12-13

The New England journal of medicine, 2017-08-31

Ann Oncol, 2020 May 11

N Engl J Med,

J Clin Oncol, 2020 Aug 11

J Thorac Oncol,

The New England journal of medicine, 2018-11-22

Lancet, 2017 Jan 24

Cancer discovery, 2016-10

The Lancet. Oncology, 2014-09

Cancer Sci,

Journal of clinical pharmacology, 2018-12

Investigational new drugs, 2023 Apr 13

Case reports in oncology, 2021 Mar 01

N Engl J Med, 2020 Sep 19

The New England journal of medicine, 2024 Apr 11

The New England journal of medicine, 2024 Jun 02